



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

February 8, 2021

Amro Albanna  
Chief Executive Officer  
Aditx Therapeutics, Inc.  
2569 Wyandotte St., Suite 101  
Mountain View, CA 94043

**Re: Aditx Therapeutics, Inc.**  
**Registration Statement on Form S-1**  
**Filed February 4, 2021**  
**File No. 333-252711**

Dear Mr. Albanna:

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact David Gessert at 202-551-2326 with any questions.

Sincerely,

Division of Corporation Finance  
Office of Life Sciences